Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Chander Peddaboina"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/bffa6301ff2f495f8400f23d5eb82290
Autor:
Arnima Bisht, Murray Cox, Antonn Cheeseman, Christian Rohlff, Chander Peddaboina, Abderrahim Fandi
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Marcene Grimsley, Binu Tharakan, Madhava R. Beeram, Bobby Darnell Robinson, Kevin Paul Varghese, Chinchusha Anasooya Shaji, Himakarnika Alluri, Shenyuan L. Zhang, Chander Peddaboina, Jason H. Huang
Publikováno v:
Journal of Biological Chemistry. 291:26958-26969
Blood-brain barrier (BBB) breakdown and the associated microvascular hyperpermeability followed by brain edema are hallmark features of several brain pathologies, including traumatic brain injuries (TBI). Recent studies indicate that pro-inflammatory
Autor:
M. Karen Newell-Rogers, Anatoliy A. Gashev, David C. Zawieja, Richard P Tobin, Olga Yu. Gasheva, Giuseppina Dusio, Chander Peddaboina, Hunter Skoog, Cynthia J. Meininger, Irina Tsoy Nizamutdinova
Publikováno v:
Aging (Albany NY)
This study aimed to establish mechanistic links between the aging-associated changes in the functional status of mast cells and the altered responses of mesenteric tissue and mesenteric lymphatic vessels (MLVs) to acute inflammation. We used an in vi
Autor:
James Edward Ackroyd, Chander Peddaboina, Eugene Zhukovsky, Arnima Bisht, Lindsey Hudson, San Lin Lou, Robert Boyd, Abderrahim Fandi, Livija Deban, Martin Barnes, Angelo Kaplan, Christian Rohlff, Murray Cox, Jason D. Allen, Nickolas Attanasio
Publikováno v:
Cancer Research. 80:5167-5167
Identification of novel targets in cancer immunotherapy is needed to address the significant number of patients that either do not respond to current therapies or encounter unacceptable toxicities. The first two generations of immuno-oncology drugs h
Autor:
Syeda H, Afroze, Chander, Peddaboina, Anthony B, McDowell, A H M Zuberi, Ashraf, Timothy C, McCormick, M Karen, Newell-Rogers, David C, Zawieja, Thomas J, Kuehl, Mohammad N, Uddin
Publikováno v:
Anticancer research. 38(10)
Cinobufotalin (CINO), a cardiotonic steroid, has been used as an anticancer agent. This study assessed the cell-specific effect of CINO on SK-OV-3, CRL-1978 and CRL-11731 ovarian cancer cells which differ in terms of their respective karyotypes.Cell
Autor:
Paul T. Wilder, Roy W. Smythe, M. Karen Newell-Rogers, Xiaobo Cao, Kwan-Young Jung, Jeremy L. Yap, Arun Rai, Weihua Jiang, Steven Fletcher, Wenbo Yu, Dan Jupitor, Alexander D. MacKerell, Harry T. Papaconstantinou, Richard P Tubin, Chander Peddaboina, Kenno Vanommeslaeghe
Publikováno v:
Molecular Cancer
Background It has been shown in many solid tumors that the overexpression of the pro-survival Bcl-2 family members Bcl-2/Bcl-xL and Mcl-1 confers resistance to a variety of chemotherapeutic agents. We designed the BH3 α-helix mimetic JY-1-106 to eng
Autor:
Philip A. Rascoe, Daniel C. Jupiter, Richard P Tobin, Jeremy L. Yap, Arun Rai, M. Karen Newell Rogers, Weihua Jiang, Steven Fletcher, W. Roy Smythe, Xiaobo Cao, Chander Peddaboina
Publikováno v:
BMC Cancer
BMC Cancer, Vol 12, Iss 1, p 541 (2012)
BMC Cancer, Vol 12, Iss 1, p 541 (2012)
Background It has been shown in many solid tumors that the overexpression of the pro-survival Bcl-2 family members Bcl-xL and Mcl-1 confers resistance to a variety of chemotherapeutic agents. Mcl-1 is a critical survival protein in a variety of cell
Autor:
Alexander D. MacKerell, Jeremy L. Yap, Xiaobo Cao, W. Roy Smythe, Kwan-Young Jung, Steven Fletcher, Paul T. Wilder, Chander Peddaboina, Kenno Vanommeslaeghe, Anjan Nan
Publikováno v:
Organicbiomolecular chemistry. 10(15)
By conducting a structure-activity relationship study of the backbone of a series of oligoamide-foldamer-based α-helix mimetics of the Bak BH3 helix, we have identified especially potent inhibitors of Bcl-x(L). The most potent compound has a K(i) va
Publikováno v:
Molecular Cancer
Molecular Cancer, Vol 9, Iss 1, p 110 (2010)
Molecular Cancer, Vol 9, Iss 1, p 110 (2010)
Background Bortezomib, a proteasome-specific inhibitor, has emerged as a promising cancer therapeutic agent. However, development of resistance to bortezomib may pose a challenge to effective anticancer therapy. Therefore, characterization of cellula